Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Sponsor: Shuangyue Liu
Summary
This study aimed to evaluate the efficacy and safety of Dalpiciclib combined with Letrozole in the maintenance treatment of HR positive and HER2 negative metastatic breast cancer after first-line chemotherapy.
Official title: A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
178
Start Date
2023-12-01
Completion Date
2028-06-30
Last Updated
2023-08-07
Healthy Volunteers
No
Conditions
Interventions
Dalpiciclib combined with Letrozole
A multicenter, single arm, prospective Phase II clinical study
Locations (1)
West China Hospital, Sichuan University
Chengdu, Sichuan, China